A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Lorlatinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CROWN
- Sponsors Pfizer
- 15 Jan 2019 Planned End Date changed from 30 Dec 2023 to 31 Jan 2024.
- 08 Jan 2019 This study has been discontinued in Denmark.
- 07 Dec 2018 Planned primary completion date changed from 17 Feb 2020 to 31 Dec 2020.